TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01961336
Drug: Testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg of testosterone gel applied on the external side of the thigh for 21 days starting from the first day of menstruation prior to initiation of ovarian stimulation with rFSH for IVF/ICSI
Study: NCT04777045
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo capsules, given QD per oral use. Placebo capsules will be used in the same manner with the same dose titration.
Study: NCT01296698
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage Form: Oral NRT; Dose: 0 mg; Frequency: up to 4 times per hour; Duration: 12 weeks
Study: NCT02687932
Drug: LCZ696
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02395042
Drug: LiRIS®
Approvals — FDA: no, EMA: no, PMDA: no
Description: LiRIS® is a drug-device combination product which is placed in the bladder during cystoscopy and remains in the bladder, gradually releasing lidocaine until removed from the bladder via cystoscopy.
Study: NCT02395042
Drug: LiRIS Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: LiRIS placebo is a drug-device combination product, matching the LiRIS® which is placed in the bladder during cystoscopy, remains in the bladder until removed from the bladder via cystoscopy
Study: NCT04110860
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: the same procedure as before is used to prepare the nanoemulsion intermediate gel but the active ingredient, voriconazole, is not added then applied twice daily in the same manner
Study: NCT03064568
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03965871
Drug: Placebo DPI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo DPI is to be administered via dry powder inhaler.
Study: NCT00994981
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thirty minutes after the beginning of the anhepatic phase, the patients were received 100 ml of normal saline over 20 minutes. A resident anesthesiologist, who was blinded to the group assignment, performed intravenous administration of the study solution and assessed study outcomes.
Study: NCT00628758
Drug: Symbicort TBH - Turbuhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symbicort Single Inhaler Therapy ( Turbuhaler 160/4.5 microgram, 1 inhalation bid + as needed)
Study: NCT00628758
Drug: beta-II-agonist, inhale steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbulin inh. 200-400 dosage 100 microgram (mcg)/dosage Salbutamol Sustained Release(SR)capsule 4 mg/8 mg Salbutol tablet (tb) 2 mg Salbutol forte syrup 2 mg/5 ml Ventolin tb, syrup, intravenous(IV),5mgx10 ampule(amp) Ventolin inhaler (inh) 200 dosage, 100 mcg/dosage Ventolin nebul 2.5 mg Volmax tb 4 mg/8 mg Vent-o-sal inh 100 mcg/200 dosage Combivent inh 100 mcg/dosage Combivent neb 2.5 mg/dosage Bricanyl tb 2.5 mg Bricanyl durules ret tb 5 mg Bricanyl syrup 30mg Bricanyl inhaler 0.25 mg/dosage, 400 dosage Bricanyl turbuhaler 0.5 mg/dosage, 200dosage
Study: NCT03867110
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03897257
Drug: UHE-103A1 cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational mono-therapy cream (containing drug A \[low dose\]). Drug A is an antifungal agent.
Study: NCT03897257
Drug: UHE-103B cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparator mono-therapy cream (containing drug B). Drug B is a keratolytic agent.
Study: NCT04348305
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Continuous infusion: 200 mg (104 ml) every 24 hours, Bolus injections: 50 mg (10 ml) every 6 hours, Total treatment duration: 7 days
Study: NCT02061202
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo training inhaler with the same instructions as the experimental group.
Study: NCT01533493
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memantine-matched placebo will be prescribed following approved FDA dosing guidelines for Alzheimer's dementia, beginning at 5mg in AM and increasing in BID doses by 5mg weekly to a maximum dose of 10mg BID.
Study: NCT02612311
Drug: TGR-1202
Approvals — FDA: no, EMA: no, PMDA: no
Description: TGR-1202: Oral daily dose
Study: NCT00686010
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet, 3 tablets, oral, once daily after breakfast
Study: NCT02651220
Drug: Epiduo® Forte Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adapalene and Benzoyl Peroxide Gel, 0.3%/2.5% w/w
Study: NCT02651220
Drug: placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: vehicle used as placebo
Study: NCT00501865
Drug: GW273225
Approvals — FDA: no, EMA: no, PMDA: no
Description: GW273225 will be available as white tablets containing 25 mg GW273225.The study drug will be taken with 240 milliliters of water at room temperature.
Study: NCT01399866
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00383162
Drug: Combination Product (sumatriptan succinate / naproxen sodium)
Normalized name: naproxen sodium / sumatriptan Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilayer tablet containing 85mg sumatriptan (as 119mg sumatriptan succinate; fast disintegrating/rapid release formulation) active ingredient in one layer, and 500mg naproxen sodium active ingredient in the second layer.
Study: NCT00383162
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablet.
Study: NCT00006136
Drug: arginine butyrate
Normalized name: butyrate
DrugBank: Butyric Acid (DB03568)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03298009
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-week intervention
Study: NCT00796380
Drug: Xingnaojing
Approvals — FDA: no, EMA: no, PMDA: no
Description: injection
Study: NCT03088267
Drug: Placebo extended-release oral suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6, 7 or 8 mL PO
Study: NCT05261152
Drug: drug product: capsules are containing S. boulardii, administered twice daily (250 mg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomisation: 1:1 Capsules containing S. boulardii twice daily (250 mg) or indistinguishable capsules containing placebo twice daily.
Study: NCT03508648
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will not be provided with any study treatments and will be off-drug during this extension study. Intervention was administered during study G201002.
Study: NCT01602549
Drug: GSK962040 (25 mg tablet)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg tablet
Study: NCT01602549
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo tablet
Study: NCT00003298
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Postoperative regimen 5-FU, along with Leucovorin, was given by IV bolus, with 5-FU given immediately after the Leucovorin
Study: NCT00003298
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Both 5-FU and Leucovorin will be given via IV bolus, with Leucovorin given immediately before 5-FU.
Study: NCT00514735
Drug: Class I or III Antiarrhythmic Medications
Normalized name: ANTIARRHYTHMICS, CLASS I AND III
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm 2 (Medical Management): Class I or III antiarrhythmic drugs. Changes in dosing, antiarrhythmic drugs or combinations of antiarrhythmic drugs were allowed. Direct current cardioversions were also allowed at the discretion of the investigator.
Study: NCT00695643
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 g per day
Study: NCT03156790
Drug: Spectrila®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 intravenous doses of 10 000 U/m² BSA each during induction phase I of the underlying BRALL 2014 treatment protocol on Days 21, 23 and 25. Additionally, the subjects (standard risk subjects only) will receive doses of 10 000 U/m² BSA each on Days 2, 4, 6, 9, 11 and 13 of the consolidation phase II, III and VI of BRALL 2014 treatment protocol.
Study: NCT01570829
Drug: Dietressa
Normalized name: Malmea depressa bark extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration.
Study: NCT01570829
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration.
Study: NCT00794885
Drug: Enalapril/folic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril/folic acid, (10mg enalapril/0.8mg folic acid)/tablet, taken orally and once daily for a maximum of 5 years. Combination with other anti-hypertension drugs are allowed.
Study: NCT01005758
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01005758
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01005758
Drug: hydrocortisone sodium succinate
Normalized name: Hydrocortisone Sodium Succinate
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01005758
Drug: mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01005758
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01005758
Drug: prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04899453
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400ug intravitreal injection every week for 4 doses in the induction phase, every 2 weeks for 2 doses as consolidation, then every month for 10 doses
Study: NCT01407445
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet/ oral/ 3 times a day for 90 days
Study: NCT00035529
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution, i.v infusion, 0 mg, Days 1 \& 15 then monthly, 10 months.
Study: NCT00451516
Drug: Herbal medicine (St. John's wort and Kava)
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02760316
Drug: AZD9567 10 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral suspension Multiple doses 5 days of treatment Once daily
Study: NCT02760316
Drug: AZD9567 20 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral suspension Multiple doses 5 days of treatment Once daily
Study: NCT02760316
Drug: AZD9567 40 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral suspension Multiple doses 5 days of treatment Once daily
Study: NCT02760316
Drug: AZD9567 80 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral suspension Multiple doses 5 days of treatment Once daily
Study: NCT02760316
Drug: Prednisolone 20 mg
Normalized name: prednisolone 20 MG
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Multiple doses 5 days of treatment Once daily
Study: NCT02760316
Drug: AZD9567 125 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Multiple doses 5 days of treatment Once daily
Study: NCT02760316
Drug: AZD9567 155 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Multiple doses 5 days of treatment Once daily
Study: NCT02760316
Drug: Prednisolone 5 mg
Normalized name: prednisolone 5 MG
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Multiple doses 5 days of treatment Once daily
Study: NCT02760316
Drug: Prednisolone 40 mg
Normalized name: prednisolone 40 MG/ML
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Multiple doses 5 days of treatment Once daily
Study: NCT00235716
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebos for dl-alpha-tocopherol and memantine.
Study: NCT00400335
Drug: Nanomilled testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00862134
Drug: PR104
Normalized name: PR104
Approvals — FDA: no, EMA: no, PMDA: no
Description: 770 mg/m\^2, IV, every 21 days. Number of Cycles: until progression or unacceptable toxicity develops.
Study: NCT03184987
Drug: FF/UMEC/VI 100/62.5/25 mcg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will self-administer the study treatment via the ELLIPTA device. The ELLIPTA holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 100 mcg in each blister and the second strip contains UMEC 62.5 mcg and VI 25 mcg in each blister. ELLIPTA is a registered trademark of GSK groups of companies.
Study: NCT01817959
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion at a volume/rate matching active treatment.The placebo was to be administered as well as an add-on treatment for the immunosuppressant regimen.
Study: NCT03262441
Drug: Mycophenolate Mofetil 500Mg Tab
Normalized name: MYCOPHENOLATE MOFETIL 500MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg once daily for one week. If tolerating the drug, then initiate twice daily for 22 months
Study: NCT00923845
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclosporine: 2 mg/kg every 12 hours PO or IV starting on day -4 of hematopoietic stem cell transplant (HSCT)
Study: NCT03546088
Drug: Topical anaesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anaesthesia with lidocaine will be provided through nebulisation and instillation. The intubating tube will be lubricated with a gel containing lidocaine.
Study: NCT01810315
Drug: TFV 1% gel
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03851055
Drug: Zinc
Normalized name: Zinc
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One arm will receive Zinc Second arm will receive placebo
Study: NCT00559988
Drug: Physician-Directed OAC
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive physician-directed anticoagulation therapy based on conventional criteria.~OAC drugs used: Dabigatran etexilate, Rivaroxaban, Warfarin, other approved VKA
Study: NCT02678923
Drug: MDCO-216
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02678923
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00311259
Drug: Melatonin (drug)
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00914329
Drug: Gelsemium Sempervirens
Normalized name: Gelsemium sempervirens
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5CH, one dose of globules morning and evening during 2 days plus one dose the morning of the day of the stress-test.
Study: NCT00914329
Drug: Gelsemium Sempervirens
Normalized name: Gelsemium sempervirens
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15CH, one dose of globules morning and evening during 2 days plus one dose the morning of the day of the stress-test.
Study: NCT00914329
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo, one dose of globules morning and evening during 2 days plus one dose the morning of the day of the stress-test.
Study: NCT01046539
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg
Study: NCT02437487
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be identical to the investigator product but will not contain product spores or non-spore solids. Placebo will consist of 92% glycerol and 8% normal saline.
Study: NCT00311259
Drug: Laktose
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02727491
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo syrup identical to active comparator in taste, appearance and volume but is inactive. Placebo comparator will be used in the placebo arm of the trial.
Study: NCT01803308
Drug: SB9200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part B randomised 6:2 (active:placebo) using recommended Part B starting dose, and ascending to up to 1500mg for 7-14 days of dosing.
Study: NCT01803308
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part B randomised 6:2 (active:placebo) using anhydrous lactose capsules identical to active comparator, minus active ingredient.
Study: NCT02638948
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo of BMS-986142 specific dose on specific days
Study: NCT02638948
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate specific dose on specific days
Study: NCT03085485
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo pills
Study: NCT02036489
Drug: Ciclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02036489
Drug: Metotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00488995
Drug: CP-675,206
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02036489
Drug: Mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02382198
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01299948
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 mg prednisolone orally per day
Study: NCT00951275
Drug: Standard DMARDs (Disease Modifying Anti Rheumatic Drugs)
Approvals — FDA: no, EMA: no, PMDA: no
Description: As prescribed
Study: NCT01536132
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (same appearance than active drug) is administered with the same dosing regime
Study: NCT04616261
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: inhalation of placebo
Study: NCT00803452
Drug: doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral doxycycline 100mg bid
Study: NCT00803452
Drug: azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: topical 1% azithromycin daily to eye
Study: NCT01183065
Drug: Pralatrexate With Vitamin B12 and Folic Acid
Normalized name: VITAMIN B12 AND FOLIC ACID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be treated with 30 mg/m2 of pralatrexate intravenously once weekly for 3 weeks in a 4 week cycle with vitamin supplementation. Patients will take 1.0-1.25 mg oral folic acid on a daily basis. Folic acid should be initiated during the 10-day period preceding the first dose of pralatrexate and dosing will be continued during the full course of therapy and for 30 days after the last dose of pralatrexate. Patients will also receive a vitamin B12 (1 mg) intramuscular injection no more than 10 weeks prior to the first dose of pralatrexate and every 8-10 weeks thereafter. Subsequent vitamin B12 injections may be given the same day as treatment with pralatrexate.
Study: NCT00416455
Drug: ferumoxtran-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Undergo femoxtran-10 MRI
Study: NCT02280317
Drug: VAL201
Approvals — FDA: no, EMA: no, PMDA: no
Description: VAL201-001 Sub-cutaneous injection.
Study: NCT02073019
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04534881
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be randomized to receive generic micronized progesterone 200 mg or placebo tablets, to be taken at bedtime daily.
Study: NCT02386826
Drug: INC280
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose Escalation: INC280 by mouth (PO) twice daily for 28 days according to the following schedule until the maximum tolerated dose (MTD) is determined:~Dose Level 1 (starting dose): 200 mg (divided dose of 100 mg twice per day) Dose Level 2: 400 mg (divided dose of 200 mg twice per day) Dose Level 3: 800 mg (divided dose of 400 mg twice per day)~Dose Expansion: INC280 PO twice daily at the MTD determined in the dose escalation phase
Study: NCT00737555
Drug: CHR-2797
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral once daily administration of capsules of CHR-2797, to determine safety and tolerability in patients being treated with paclitaxel infusion every 3 weeks for up to 18 weeks.
Study: NCT00363519
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-blind period (12 wk); placebo QD The double-blind period will be followed by a 40 wk open-label extension period where MK-0431/ONO-5435 could be titrated from 50 mg QD to 100 mg QD
Study: NCT01005056
Drug: Ethinylestradiol + Desogestrel
Normalized name: desogestrel and ethinylestradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participants receive Marvelon® according to the approved dosage and administration method.
Study: NCT03927911
Drug: Standard of Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of Care
Study: NCT00842140
Drug: Oral contraceptive plus spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The patient will receive an oral contraceptive (0,03mg ethynylestradiol and 2mg chlormadinone acetate) plus 100 mg spironolactone. One pill each once a day for twelve months.
Study: NCT01257906
Drug: CLIND PHOSPHATE (1.2%) AND TRETINOIN (0.025%) TOPICAL GEL
Normalized name: clindamycin phosphate / tretinoin Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Gel applied in the evening for 84 days
Study: NCT01257906
Drug: ZIANA®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Gel applied in the evening for 84 days
Study: NCT04365582
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 500 mg day 1 ; 250 mg/day for 4 days
Study: NCT02025803
Drug: TAS-114/capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part 1 (dose-escalation phase):~Treatment cycles of TAS-114 and capecitabine orally BID for 14 days followed by 7 days rest until at least one of the discontinuation criteria are met TAS-114 dose starting at 20mg/m2/day with capecitabine dose of 760 mg/m2/day. TAS-114 doses will be escalated for each cohort up to 480mg/m2/day. If MTD is not reached by TAS-114 dose of 480mg/m2/day, the capecitabine dose will be escalated~Part 2 (expansion phase):~TAS-114 and capecitabine MTD established in Part 1 administered BID for 14 days followed by 7-day recovery period (21-day cycle).
Study: NCT00891163
Drug: Synera™ Topical Patch (70 mg lidocaine/70 mg tetracaine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 minute applicable on antecubital fossa
Study: NCT00891163
Drug: Placebo Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT00863174
Drug: SPARC147709
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPARC147709 injection